Clinical Outcomes of Empagliflozin in the Treatment of Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review shows empagliflozin reduces first HF hospitalization and total HF events in patients, suggesting its effectiveness.

Empagliflozin significantly reduced first heart failure hospitalization and total adverse events among patients.
In a meta-analysis of 13 RCTs with 72,871 heart failure patients, empagliflozin showed favorable outcomes versus placebo.
The systematic review analyzed data following PRISMA guidelines and used RevMan software for pooled analysis.
Empagliflozin may enhance treatment strategies for acute heart failure, warranting further investigation and validation.

Azam et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark